FDA Guidance Document: Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up

This U.S. Food and Drug Administration (FDA) guidance provides recommendations for testing for Replication-Competent Retrovirus (RCR) in retroviral vector-based gene therapy products. The document outlines a comprehensive testing strategy to mitigate the significant safety risks associated with RCR, which can emerge during vector manufacturing and cause serious adverse events in patients. It covers testing requirements for manufacturing intermediates, the final drug product, and long-term patient monitoring after product administration.

This guidance applies to retroviral vector-based products, including gammaretroviral vectors and, with adaptations, lentiviral vectors.

• Core Risk: RCRs are infectious viral particles that can be generated through recombination events during the manufacturing of replication-deficient retroviral vectors. They pose a significant risk to patients, including the potential for insertional mutagenesis leading to cancer.
• Manufacturing Testing Strategy: The guidance recommends a multi-stage testing approach to ensure the final product is free of RCR. Testing should occur cumulatively at multiple stages (MCB, VPC, vector harvests, and final ex vivo products) to confirm absence of RCR at each critical point.
• Patient Follow-Up and Monitoring: Due to the potential for RCR to emerge after administration, long-term patient monitoring is critical. Recommendations include:
  • Collecting and testing patient samples (e.g., peripheral blood cells) for RCR at baseline and at specific intervals post-infusion (e.g., 3, 6, and 12 months, then annually).
  • The duration may extend up to 15 years depending on vector type, integration risk, and clinical context.
  • Archiving patient samples for future analysis.
• Assay Recommendations: The guidance recommends using sensitive, validated biological assays (e.g., cell-culture based infectivity assays) complemented by molecular methods like PCR. Biological infectivity assays are primary; PCR and molecular assays serve as supportive but not sole testing methods.
• Action Plan: Sponsors should have a clear plan in place for managing a positive RCR result, including confirmatory testing, patient evaluation, and prompt reporting to the FDA. And if confirmed, sponsors must investigate manufacturing processes, assess patient risk, and notify FDA—potentially resulting in clinical hold until resolved.